School of Pharmaceutical Science, Health Science Center, Shenzhen University, Shenzhen, China.
Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Skin Res Technol. 2023 Jul;29(7):e13405. doi: 10.1111/srt.13405.
To investigate the effects of secukinumab treatment for psoriasis on different functional cytokines and inflammatory mediators in patients' serum METHODS: Enzyme-linked immunosorbent assay was used to detect interleukin (IL)-1β and IL-1RA associated with intrinsic immunity; IL-6, IL-18, and growth regulated oncogene alpha (GROα) associated with neutrophils; IL-12, tumour necrosis factor (TNF)-α, and interferon (IFN)-γ associated with Th1; IL-23, IL-17A, and IL-22 associated with Th17; Thymus activation regulated chemokine (TARC), IL-13, and defensin beta 2 (DEFB2) associated with Th2; Vascular endothelial growth factor (VEGF)-A and IL-10 associated with angiogenesis; and IFN-γ associated with sepsis in the peripheral blood of 12 patients with common psoriasis treated with secukinumab and 15 healthy controls. IL-23, IL-17A, IL-22 associated with Th17; TARC, IL-13, DEFB2 associated with Th2; VEGF-A, IL-10 associated with angiogenesis and procalcitonin (PCT) associated with sepsis. The differences in expression of the above cytokines before and after treatment and the correlation with psoriasis disease severity［Psoriasis Area Severity Index(PASI) score］, age, and disease duration were analyzed.
The mean PASI score of the enrolled patients with moderate to severe psoriasis was 21.6 ± 11.0 before treatment and decreased to below 1 after treatment. Serum IL-6; IL-18, GROα, IFN-γ, TNF-α, VEGF-A, and IL-17A were significantly higher than normal. And IL-17A and IFN-γ were positively correlated with disease duration and age, and IL-18 was positively correlated with PASI score. The expression levels of IL-6, GROα, VEGF-A, IFN-γ, TNF-α, IL-17A and IL-23 were significantly lower after secukinumab treatment compared with those before treatment, but the expression levels of IFN-γ, VEGF-A, TARC, IL-13, and DEFB2 were still significantly higher than those of normal subjects after treatment CONCLUSIONS: secukinumab clears skin lesions by antagonizing IL-17A and simultaneously decreasing the expression levels of IL-6, GRO α, VEGF-A, IFN-γ, TNF-α, IL-17A, and IL-23.
研究司库奇尤单抗治疗银屑病对患者血清中不同功能细胞因子和炎症介质的影响。
采用酶联免疫吸附试验检测固有免疫相关的白细胞介素（IL）-1β和 IL-1RA；中性粒细胞相关的 IL-6、IL-18 和生长调节致癌基因α（GROα）；Th1 相关的 IL-12、肿瘤坏死因子（TNF）-α和干扰素（IFN）-γ；Th17 相关的 IL-23、IL-17A 和 IL-22；Th2 相关的 Thymus activation regulated chemokine（TARC）、IL-13 和 defensin beta 2（DEFB2）；血管内皮生长因子（VEGF）-A 和 IL-10 相关的血管生成；以及外周血中 IFN-γ与脓毒症相关。
12 例寻常型银屑病患者接受司库奇尤单抗治疗前后，外周血中 IL-23、IL-17A、IL-22 与 Th17 相关；TARC、IL-13、DEFB2 与 Th2 相关；VEGF-A、IL-10 与血管生成相关；降钙素原（PCT）与脓毒症相关。
司库奇尤单抗通过拮抗 IL-17A 清除皮肤病变，同时降低 IL-6、GROα、VEGF-A、IFN-γ、TNF-α、IL-17A 和 IL-23 的表达水平。
